Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex (Nasdaq: VRTX) announced Phase 4 data showing JOURNAVX (suzetrigine) enabled opioid-free recovery in plastic surgical patients. In a 99-patient, open-label study, 90.9% were opioid free through treatment (up to 14 days) and 90.7% rated effectiveness as excellent, very good, or good (95% CI: 83.1%, 95.7%). No serious adverse events related to JOURNAVX were reported. Data accepted for oral presentation at AAPM PainConnect 2026 on March 6, 2026.
Vertex (NASDAQ: VRTX) management will participate in TD Cowen’s 46th Annual Health Care Conference on March 3, 2026. CEO Reshma Kewalramani will appear in a fireside chat at 9:10 a.m. ET. A live webcast and archived replay will be available in the Investors > News and Events section.
Vertex (NASDAQ: VRTX) reported strong commercial results and guidance on February 12, 2026. Full year 2025 total revenue was $12.0 billion (+9% year-over-year) and Q4 2025 revenue was $3.19 billion (+10% year-over-year). GAAP net income was $4.0 billion and non-GAAP net income was $4.7 billion. Cash and marketable securities totaled $12.3 billion at year-end.
Vertex provided 2026 guidance of $12.95–$13.1 billion total revenue and at least $0.5 billion from non-CF products, with combined GAAP R&D, AIPR&D and SG&A expense guidance of $6.3–$6.45 billion.
WuXi Biologics and Vertex (VRTX) signed a license and research service agreement dated Feb 2, 2026, covering an innovative trispecific T‑cell Engager (TCE) for B‑cell mediated autoimmune diseases.
Vertex receives exclusive global development and commercialization rights at the preclinical stage; WuXi Biologics will receive an upfront payment, potential development/regulatory/sales milestones and royalties, and will provide contract R&D services on next‑generation TCEs.
Satellos (GBIO) appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs on January 29, 2026.
Ms. Paone joins from Generation Bio where she served as Chief Operating Officer and previously led regulatory strategy at Vertex, including work on Kalydeco and Orkambi. Satellos says her hire supports advancement of two SAT-3247 clinical studies in adult and pediatric DMD populations.
Vertex (NASDAQ: VRTX) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. The company will host a conference call and webcast at 4:30 p.m. ET.
Dial-in numbers: (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The live webcast will be available in the Investors section of Vertex's website and an archived webcast will be posted. Participants are recommended to register at least 15 minutes before the webcast to ensure timely connection.
Vertex (Nasdaq: VRTX) provided business and pipeline updates ahead of investor meetings and a webcast at the J.P. Morgan Healthcare Conference on January 12, 2026. Key commercial milestones in 2025 include >$100 million in CASGEVY revenue and >500,000 JOURNAVX prescriptions with access for ~200 million covered lives. Vertex reported multiple regulatory and clinical milestones: a rolling BLA for povetacicept with priority review voucher and Breakthrough designation, RAINIER full enrollment, planned pivotal submissions for CASGEVY pediatric use in H1 2026, and several mid/late‑stage studies delivering data or completing enrollment across CF, renal, pain, and other programs.
Vertex (Nasdaq: VRTX) announced that Dr. Reshma Kewalramani, CEO and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. ET / 2:15 p.m. PT.
A live webcast of management's remarks will be available in the company's Investors > News and Events section at www.vrtx.com, and a replay will be archived on the website.
Vertex (Nasdaq: VRTX) presented first-ever pivotal data for CASGEVY in children ages 5–11 with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) at ASH and announced plans for global regulatory submissions in 1H 2026.
In 5–11 patients, SCD results showed VOC-free outcomes (VF12) in all patients with sufficient follow-up and TDT patients achieved transfusion independence (TI12) in all with sufficient follow-up. Longer-term data in ages ≥12 continued to show durable benefits: 100% VF12 (45/45) in SCD and 98.2% TI12 (55/56) in TDT with multi-year mean durations. Safety was consistent with myeloablative conditioning and autologous transplant; one pediatric death related to conditioning-associated veno-occlusive disease was reported.
Vertex (Nasdaq: VRTX) announced that senior management will participate in Citi’s 2025 Global Healthcare Conference on Wednesday, December 3, 2025 at 9:00 a.m. ET.
Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will take part in a fireside chat. A live webcast of management’s remarks will be available on Vertex’s investor website, and a replay will be archived on the company's site.